Literature DB >> 23456445

Association of thromboxane A2 receptor gene polymorphisms with cerebral infarction in a Chinese population.

Jing Zhao1, Lan Zheng, Qingzhou Fei, Yi Fu, Yingfeng Weng, Hui Wu, Huanyin Li, Qi Jun, Jingshan Shao, Yuming Xu.   

Abstract

Platelet aggregation is crucial for the development of cerebral infarction (CI) and it is markedly increased due to the binding of thromboxane A2 (TXA2) to its receptor (TXA2R). Therefore, TXA2R plays a central role in the pathogenesis of atherosclerosis and thrombosis. This study aimed to investigate the relationship between human TXA2R gene single nucleotide polymorphisms (SNPs) and non-cardiogenic CI in a Chinese cohort. Two SNPs, rs768963 and rs4523, located in the regulatory and coding regions of TXA2R gene, respectively, were examined in DNA samples from 407 Chinese patients with CI and 270 controls. 407 CI was categorized into subtypes using Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. There was no significant association between rs4523 variants and CI. However, there was a significant difference in the overall distribution of genotypes and dominant/recessive models of rs768963 between CI and control groups. In addition, multiple logistic regression analysis revealed that the C allele of rs768963 was significantly associated with total CI (P = 0.023), large artery atherosclerosis subtype (P = 0.009), small artery occlusion subtype (P = 0.044) after adjusting for confounding factors (odds ratio = 1.533, 1.918 and 1.573, respectively). We conclude that TXA2R rs768963 polymorphism is associated with CI in a Chinese population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456445     DOI: 10.1007/s10072-013-1340-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

1.  SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction.

Authors:  A Yaël Nossent; Jakob L Hansen; Carine Doggen; Paul H A Quax; Søren P Sheikh; Frits R Rosendaal
Journal:  Am J Hypertens       Date:  2011-06-16       Impact factor: 2.689

2.  Relationship between the thromboxane A2 receptor gene and susceptibility to cerebral infarction.

Authors:  Yoshiyuki Kaneko; Tomohiro Nakayama; Kosuke Saito; Akihiko Morita; Ichiro Sato; Aya Maruyama; Masayoshi Soma; Teruyuki Takahashi; Naoyuki Sato
Journal:  Hypertens Res       Date:  2006-09       Impact factor: 3.872

3.  Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults.

Authors:  Alessandro Pezzini; Mario Grassi; Elisabetta Del Zotto; Silvana Archetti; Raffaella Spezi; Veronica Vergani; Deodato Assanelli; Luigi Caimi; Alessandro Padovani
Journal:  Stroke       Date:  2005-02-03       Impact factor: 7.914

Review 4.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century.

Authors:  Valery L Feigin; Carlene M M Lawes; Derrick A Bennett; Craig S Anderson
Journal:  Lancet Neurol       Date:  2003-01       Impact factor: 44.182

5.  Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis.

Authors:  J L Mehta; D Lawson; P Mehta; T Saldeen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

6.  Activation of thromboxane receptor upregulates interleukin (IL)-1beta-induced VCAM-1 expression through JNK signaling.

Authors:  Hossein Bayat; Shanqin Xu; David Pimentel; Richard A Cohen; Bingbing Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-11-21       Impact factor: 8.311

7.  A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis.

Authors:  Andrew D Mumford; Ban B Dawood; Martina E Daly; Sherina L Murden; Michael D Williams; Majd B Protty; Jennifer C Spalton; Mark Wheatley; Stuart J Mundell; Steve P Watson
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

8.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

9.  Activation-dependent stabilization of the human thromboxane receptor: role of reactive oxygen species.

Authors:  Stephen J Wilson; Claire C Cavanagh; Allison M Lesher; Alexander J Frey; Shane E Russell; Emer M Smyth
Journal:  J Lipid Res       Date:  2009-01-16       Impact factor: 5.922

Review 10.  G-protein-coupled receptors as signaling targets for antiplatelet therapy.

Authors:  Susan S Smyth; Donna S Woulfe; Jeffrey I Weitz; Christian Gachet; Pamela B Conley; Shaun G Goodman; Matthew T Roe; Athan Kuliopulos; David J Moliterno; Patricia A French; Steven R Steinhubl; Richard C Becker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-20       Impact factor: 8.311

View more
  11 in total

1.  Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.

Authors:  Ling-Ling Peng; Yuan-Qi Zhao; Zi-Yi Zhou; Jing Jin; Min Zhao; Xin-Meng Chen; Ling-Yan Chen; Ye-Feng Cai; Jia-Li Li; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2016-09-19       Impact factor: 6.150

2.  Thromboxane A2 Receptor Stimulation Enhances Microglial Interleukin-1β and NO Biosynthesis Mediated by the Activation of ERK Pathway.

Authors:  Wanlin Yang; Aijuan Yan; Tingting Zhang; Jiaxiang Shao; Tengyuan Liu; Xiao Yang; Weiliang Xia; Yi Fu
Journal:  Front Aging Neurosci       Date:  2016-01-29       Impact factor: 5.750

3.  Thromboxane A2 receptor antagonist SQ29548 reduces ischemic stroke-induced microglia/macrophages activation and enrichment, and ameliorates brain injury.

Authors:  Aijuan Yan; Tingting Zhang; Xiao Yang; Jiaxiang Shao; Ningzhen Fu; Fanxia Shen; Yi Fu; Weiliang Xia
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

Review 4.  Pharmacogenomics of Prostaglandin and Leukotriene Receptors.

Authors:  José A Cornejo-García; James R Perkins; Raquel Jurado-Escobar; Elena García-Martín; José A Agúndez; Enrique Viguera; Natalia Pérez-Sánchez; Natalia Blanca-López
Journal:  Front Pharmacol       Date:  2016-09-21       Impact factor: 5.810

5.  Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients.

Authors:  Xingyang Yi; Jing Lin; Hua Luo; Chun Wang; Yingying Liu
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

6.  A Promising Approach to Integrally Evaluate the Disease Outcome of Cerebral Ischemic Rats Based on Multiple-Biomarker Crosstalk.

Authors:  Guimei Ran; Yixuan Wang; Haochen Liu; Chunxiang Wei; Tao Zhu; Haidong Wang; Hua He; Xiaoquan Liu
Journal:  Dis Markers       Date:  2017-05-25       Impact factor: 3.434

7.  Interactions among variants in TXA2R, P2Y12 and GPIIIa are associated with carotid plaque vulnerability in Chinese population.

Authors:  Xingyang Yi; Jing Lin; Hua Luo; Ju Zhou; Qiang Zhou; Yanfen Wang; Chun Wang
Journal:  Oncotarget       Date:  2018-04-03

8.  Association of FOXF2 gene polymorphisms with ischemic stroke in Chinese Han population.

Authors:  Chang-He Shi; Mi-Bo Tang; Shao-Hua Li; Zhi-Jie Wang; Xin-Jing Liu; Lu Zhao; Yuan Gao; Yu-Sheng Li; Shi-Lei Sun; Jun Wu; Bo Song; Yu-Ming Xu
Journal:  Oncotarget       Date:  2017-09-23

Review 9.  Genetic Variants behind Cardiovascular Diseases and Dementia.

Authors:  Wei-Min Ho; Yah-Yuan Wu; Yi-Chun Chen
Journal:  Genes (Basel)       Date:  2020-12-18       Impact factor: 4.096

Review 10.  G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential.

Authors:  Zeinab Vahidinia; Mohammad Taghi Joghataei; Cordian Beyer; Mohammad Karimian; Abolfazl Azami Tameh
Journal:  Mol Neurobiol       Date:  2021-06-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.